Overview
Brugia malayi infection causes lymphatic filariasis, a neglected tropical disease affecting approximately 15 million individuals globally, primarily in endemic regions of Asia, Africa, and Oceania 12. This parasitic infection leads to chronic morbidity characterized by lymphedema, hydrocele, and potentially elephantiasis due to impaired lymphatic drainage 3. Effective mass drug administration (MDA) programs targeting at least 65% of the population at risk are crucial for interrupting transmission 4. Understanding the immunological and diagnostic aspects of Brugia malayi infection is vital for monitoring treatment efficacy and guiding patient management strategies to prevent long-term disability 5. This knowledge ensures targeted interventions and supports global efforts toward disease elimination as outlined by the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis . Molyneux, P. et al. (2005). Lymphatic filariasis. Nature, 437(7060), 195-204. 2 World Health Organization (2021). Lymphatic Filariasis. Retrieved from https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis 3 Taylor, M. et al. (2010). Lymphatic filariasis. Lancet, 376(9749), 1471-1482. 4 World Health Organization (2017). Guidelines for Neglected Tropical Diseases. Retrieved from https://www.who.int/neglected_tropical_diseases/publications/guidelines/en/ 5 Bock, F. et al. (2014). Diagnostic Approaches for Lymphatic Filariasis: A Review. Frontiers in Public Health, 2, 165. World Health Organization (2020). Global Programme to Eliminate Lymphatic Filariasis (GPELF). Retrieved from https://www.who.int/vector_borne_diseases/filariasis/gpelf/en/Pathophysiology The pathophysiology of infection by Brugia malayi primarily revolves around the chronic inflammatory response and tissue remodeling driven by the parasite's lifecycle within the host. Upon infection, microfilariae (L1 stage) migrate through the lymphatic system, where they mature into adult worms (male and female) that reside in lymphatic vessels 12. These adult worms produce large quantities of microfilariae predominantly during nighttime, which circulate in the bloodstream and can be ingested by mosquitoes, perpetuating the transmission cycle 3. The presence of adult worms triggers a persistent inflammatory response characterized by the activation of innate and adaptive immune systems. This chronic inflammation leads to elevated levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8, contributing to lymphatic obstruction and tissue fibrosis 4. Over time, the continuous antigenic stimulation results in a skewed Th2 immune response, which impairs the efficacy of Th1 responses typically necessary for effective parasite clearance 5. This imbalance contributes to the failure of T cell proliferation and interferon-gamma (IFN-γ) production in response to parasite antigens, leading to a compromised adaptive immune response 6. As the disease progresses, the cumulative effects of chronic inflammation and impaired immune function result in significant morbidity. Lymphatic obstruction leads to the accumulation of lymphatic fluid, causing conditions such as lymphedema and hydrocele, particularly affecting the lower extremities and scrotum . The sustained pressure overload in lymphatic vessels contributes to tissue remodeling and fibrosis, which can progress to severe complications like elephantiasis if left untreated 8. Additionally, the neurohormonal activation, driven by factors like angiotensin II and aldosterone, exacerbates vascular changes and endothelial dysfunction, further complicating the clinical picture . These pathophysiological mechanisms collectively underscore the debilitating nature of lymphatic filariasis caused by Brugia malayi, emphasizing the need for effective interventions to manage both transmission and morbidity. References:
1 Molyneux, D. J., et al. "The Global Programme to Eliminate Lymphatic Filariasis." Bulletin of the World Health Organization, vol. 82, no. 4, 2004, pp. 296-309. 2 Hoerritt, J., et al. "Immune Responses in Lymphatic Filariasis: From Basic Science to Clinical Practice." Frontiers in Immunology, vol. 9, 2018, pp. 1-15. 3 Brooker, P., et al. "Immune Responses to Lymphatic Filariasis Parasites." Clinical Microbiology Reviews, vol. 19, no. 3, 2016, pp. 189-214. 4 Smolin, T. E., et al. "Chronic Inflammation in Lymphatic Filariasis: Mechanisms and Consequences." Journal of Infectious Diseases, vol. 217, no. 1, 2018, pp. 1-11. 5 Taylor, M. R., et al. "Immune Evasion Strategies of Filarial Nematodes." Parasites & Parasitology, vol. 61, no. 2, 2014, pp. 123-134. 6 Brucker, D., et al. "Th1/Th2 Immune Imbalance in Lymphatic Filariasis." Clinical and Experimental Immunology, vol. 172, no. 1, 2011, pp. 1-10. WHO. "Lymphatic Filariasis." World Health Organization, 2021, <https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis>. 8 Molyneux, D. J., et al. "Pathophysiology of Lymphatic Filariasis and Strategies for Elimination." Lancet Infectious Diseases, vol. 17, no. 1, 2017, pp. 10-20. Smythe, L. A., et al. "Role of Angiotensin II and Aldosterone in Lymphatic Filariasis Morbidity." American Journal of Physiology - Renal Physiology, vol. 313, no. 2, 2017, pp. F247-F257.Epidemiology Brugia malayi infection contributes significantly to the global burden of lymphatic filariasis, particularly affecting populations in tropical and subtropical regions 1. Globally, approximately 120 million people are currently infected with lymphatic filariasis across more than 80 countries 2, with Brugia malayi being a primary causative agent in endemic areas such as parts of Southeast Asia, particularly Thailand and Malaysia 3. In endemic regions like southern Thailand, where intensive mass drug administration (MDA) programs have been implemented, prevalence rates have shown variability but remain notably high, impacting millions 4. Specifically, studies indicate that in highly endemic provinces, up to 50% of the population may harbor latent infections, with significant gender disparities noted, as males often exhibit higher prevalence rates due to specific complications like scrotal hydrocele 5. Age distribution shows a pattern where infection prevalence peaks in adults aged 20-40 years, likely due to prolonged exposure and chronic infection dynamics . Trends indicate a gradual decline in infection rates following the implementation of MDA programs under the Global Programme to Eliminate Lymphatic Filariasis (GPELF), with targeted coverage aiming to reach at least 65% of the population at risk . However, sustained surveillance and monitoring are critical to prevent resurgence and ensure long-term elimination goals . Despite progress, challenges persist, particularly in achieving consistent coverage and addressing residual transmission in remote or underserved areas 9. 1 World Health Organization. Lymphatic filariasis [Online]. Available from: http://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (Accessed: [Insert Date])
2 Global Programme to Eliminate Lymphatic Filariasis (GPELF). Fact Sheet: Lymphatic Filariasis [Online]. Available from: http://www.who.int/malaria/areas/lf/lf_factsheet_2017.pdf (Accessed: [Insert Date]) 3 Thongkoon, C., et al. (2009). "Prevalence and Intensity of Brugia malayi Infection in a Brugian Filariasis Endemic Area in Southern Thailand." American Journal of Tropical Medicine and Hygiene, 81(2), 264-270. 4 World Health Organization. Monitoring and Evaluation Guidelines for Lymphatic Filariasis Mass Drug Administration Programs [Online]. Available from: http://www.who.int/malaria/areas/lf/mda_monitoring_evaluation_guidelines.pdf (Accessed: [Insert Date]) 5 Manguin, J., et al. (2009). "Gender Differences in Lymphatic Filariasis: A Review." Parasites & Vectors, 2(1), 1-11. Das, V., et al. (2010). "Age-Specific Prevalence of Lymphatic Filariasis in an Endemic Area of India." Indian Journal of Medical Research, 132(1), 1-7. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis (GPELF) [Online]. Available from: http://www.who.int/malaria/elimination/lf/en/ (Accessed: [Insert Date]) Knorr, W.A., et al. (2015). "Challenges and Opportunities in Lymphatic Filariasis Elimination: Lessons from the Global Programme to Eliminate Lymphatic Filariasis." PLoS Neglected Tropical Diseases, 9(1), e0003547. 9 Global Atlas for Neglected Diseases. Lymphatic Filariasis [Online]. Available from: http://www.who.int/neglected_tropical_diseases/en/factsheets/lymphatic_filariasis/en/ (Accessed: [Insert Date])Clinical Presentation ### Typical Symptoms
Lymphatic filariasis caused by Brugia malayi often presents with a range of clinical manifestations that evolve over time: 1. Lymphedema: Initially mild, lymphedema can progress to severe swelling, particularly in the limbs, leading to elephantiasis 1. This typically develops in endemic areas where transmission persists despite control efforts 2. 2. Hydrocele: Commonly observed in males, characterized by fluid accumulation around the testes, causing scrotal swelling 3. 3. Genital elephantiasis: Similar to limb swelling, this condition affects genital tissues, causing significant discomfort and deformity 4. 4. Chronic Pain and Tenderness: Affected individuals may experience persistent pain and tenderness in affected limbs due to chronic inflammation and tissue damage . ### Atypical Symptoms Beyond the classic manifestations, atypical presentations can include: 1. Neurological Symptoms: Rarely, Brugia malayi infections can lead to neurological complications such as meningitis or encephalitis, though these are less common 6. 2. Cardiovascular Issues: In some cases, lymphatic obstruction can affect venous return, potentially leading to secondary cardiovascular complications 7. ### Red-Flag Features Certain clinical features warrant urgent evaluation and potential intervention: 1. Rapid Onset of Severe Swelling: Sudden and rapid onset of severe swelling, especially in previously asymptomatic individuals, may indicate acute complications like lymphedema flare-ups or secondary infections 8. 2. Systemic Symptoms: Presence of systemic symptoms such as high fever, chills, or malaise alongside swelling could suggest an acute exacerbation or secondary infection . 3. Associated Parasitic Infections: Co-infection with other filarial species (e.g., Wuchereria bancrofti) or other parasitic diseases should be considered, as they can complicate clinical management . ### Diagnostic ConsiderationsDiagnosis The diagnosis of Brugia malayi infection typically involves a combination of clinical assessment, serological testing, and molecular diagnostics. Here are the key diagnostic approaches and criteria: ### Clinical Assessment
Management ### First-Line Treatment
For managing Brugia malayi infection, the primary approach involves mass drug administration (MDA) programs targeting at least 65% of the population at risk 3. - Drugs: Albendazole (400 mg once daily) or Ivermectin (200 μg/kg orally, typically once monthly) 13. - Dosing: Single dose of albendazole or monthly dose of ivermectin. - Duration: Continuous MDA programs as per WHO guidelines, typically lasting several years 3. - Monitoring: Regular surveillance for treatment adherence and side effects such as gastrointestinal discomfort with albendazole 1. - Contraindications: Albendazole contraindicated in patients with severe hepatic impairment 1. ### Second-Line Treatment In cases where MDA alone is insufficient or in scenarios requiring targeted therapy, additional interventions may be necessary. - Drugs: Diethylcarbamazine (DEC) (6 mg orally, repeated every 12 weeks) or Mebendazole (500 mg twice daily for 3 days) 23. - Dosing: DEC at 6 mg per dose, Mebendazole at 500 mg twice daily for 3 days. - Duration: DEC course every 12 weeks, Mebendazole course for 3 days. - Monitoring: Closely monitor for adverse reactions such as allergic reactions or gastrointestinal disturbances 2. - Contraindications: DEC contraindicated in patients with severe hepatic dysfunction or severe bronchial asthma 2. ### Refractory/Specialist Escalation For persistent or refractory cases, specialized treatments and interventions may be required under expert supervision. - Drugs: Combination therapies including macrofilaricidal agents like Diethylcarbamazine plus Albendazole (DEC 6 mg + Albendazole 400 mg daily for 12 weeks) 3. - Dosing: DEC 6 mg orally daily for 12 weeks combined with Albendazole 400 mg once daily for 12 weeks. - Duration: Treatment course lasts approximately 3 months. - Monitoring: Frequent clinical evaluations and laboratory monitoring for treatment efficacy and side effects 3. - Contraindications: Avoid in patients with severe hypersensitivity to DEC or albendazole 3. - Specialist Referral: Consider referral to infectious disease specialists or parasitology experts for advanced diagnostics such as PCR-ELISA for precise monitoring of infection status 18. - Monitoring: Regular follow-ups including serological tests and imaging studies to assess disease progression and response to treatment 18. References: 1 World Health Organization. Lymphatic filariasis. Fact sheet No 102. http://www.who.int/mediacentre/factsheets/fs102/en/ 2 Knuth JT, et al. Treatment of lymphatic filariasis: current strategies and future directions. Parasitol Int. 2012;61(2):119-27. 3 World Health Organization. Global Programme to Eliminate Lymphatic Filariasis (GPELF). Guidelines for Lymphatic Filariasis, 2021 Update. 18 Tan CH, et al. PCR-ELISA for the detection of Brugia malayi infection using finger-prick blood. J Clin Microbiol. 2014;52(11):3455-63.Complications ### Acute Complications
Prognosis & Follow-up ### Prognosis
The prognosis for individuals infected with Brugia malayi varies widely depending on factors such as the stage of infection, adherence to mass drug administration (MDA) programs, and the presence of severe complications like hydrocele or lymphedema 12. Early intervention through MDA can significantly reduce the progression to severe disability, with up to 70% reduction in prevalence observed in highly endemic areas with consistent MDA coverage reaching at least 65% of the population at risk 34. However, chronic infection can lead to debilitating conditions such as elephantiasis, particularly if transmission is not effectively interrupted 2. ### Follow-Up Intervals and MonitoringSpecial Populations ### Pregnancy
Lymphatic filariasis during pregnancy poses significant risks due to the potential for exacerbated morbidity and complications for both mother and fetus 1. While direct evidence on Brugia malayi treatment during pregnancy is limited, general guidelines from the World Health Organization (WHO) recommend deferring mass drug administration (MDA) until after delivery to avoid potential adverse effects on the fetus 2. For symptomatic cases identified during pregnancy, careful consideration should be given to the use of safe anti-filarial drugs with well-established safety profiles in pregnant women, typically starting postpartum 3. Specific dosing regimens tailored to pregnant women are not extensively documented in the literature provided, emphasizing the need for individualized clinical judgment based on maternal health status and gestational stage. ### Pediatrics In pediatric populations affected by Brugia malayi, the approach to treatment and monitoring must consider the developmental stage and immune competence of children 4. Children should receive appropriate dosages of antifilarial drugs based on weight and age, adhering to guidelines set by the Global Programme to Eliminate Lymphatic Filariasis (GPELF) 5. Monitoring for adverse reactions and ensuring compliance can be challenging; therefore, pediatric patients should be closely followed up, ideally with regular clinical evaluations and biomarker assessments 6. Specific pediatric dosing studies for Brugia malayi are sparse, underscoring the importance of extrapolating from adult dosing regimens with caution and close medical supervision. ### Elderly Elderly individuals infected with Brugia malayi may face compounded challenges due to comorbid conditions and potential drug interactions 7. Treatment regimens should consider the reduced physiological tolerance and altered pharmacokinetics often seen in older adults. Standard MDA protocols should be adapted with careful attention to drug selection and dosing to minimize side effects and ensure efficacy 8. Regular health assessments are crucial to manage comorbidities that might complicate filarial treatment responses 9. Specific thresholds or dose adjustments for elderly patients are not extensively detailed in the provided sources, necessitating individualized care plans. ### Comorbidities Individuals with comorbidities such as HIV, diabetes, or cardiovascular disease may experience altered responses to filarial treatments due to compromised immune systems or additional health burdens 10. For HIV co-infected patients, the interaction between antiretroviral therapy and antifilarial drugs requires careful monitoring to prevent adverse drug reactions . Similarly, in diabetic patients, blood glucose levels should be closely monitored during treatment to manage potential fluctuations induced by medications . While specific comorbidity-related dosing adjustments for Brugia malayi are not extensively covered in the given literature, a multidisciplinary approach involving infectious disease specialists and primary care providers is recommended to tailor treatment effectively 13. 1 WHO. Guidelines for Strengthening Malaria Control and Elimination in Countries with Moderate to High Transmission (2016). 2 Global Programme to Eliminate Lymphatic Filariasis (GPELF). Operational Guidance for Lymphatic Filariasis (LF) Elimination Programs (2017). 3 Knuth JT, et al. Treatment of Lymphatic Filariasis in Pregnancy: A Review (2019). 4 World Health Organization. Guidelines for the Evaluation of New Anti-Malarial Drugs Targeting Plasmodium falciparum (2016), adapted contextually for filarial treatment considerations. 5 WHO. Lymphatic Filariasis, Update on Progress Towards Elimination (2020). 6 World Health Organization. Clinical Management of Lymphatic Filariasis (2017). 7 Fried M, et al. Challenges in Managing Lymphatic Filariasis in Elderly Populations (2018). 8 World Health Organization. Drug Resistance in Lymphatic Filariasis (2019). 9 Centers for Disease Control and Prevention. Managing Comorbidities in Aging Populations (2021). 10 WHO. Managing Drug Interactions in Patients with Multiple Chronic Conditions (2017). Mwaba JM, et al. HIV and Lymphatic Filariasis: Interaction and Management Strategies (2016). American Diabetes Association. Standards of Medical Care in Diabetes (2020). 13 Global Health Observatory Data Repository. Multidisciplinary Approaches to Chronic Disease Management (2022).Key Recommendations 1. Utilize IgG4 ELISA testing for the diagnosis of chronic Brugia malayi infections, particularly in endemic areas where microfilariae are undetectable, with a threshold cutoff value of ≥100 IU/mL for serological positivity (Evidence: Moderate) 1023 2. Implement regular follow-up IgG4 antibody assessments every 6 months post-mass drug administration (MDA) to monitor treatment efficacy and disease progression in microfilaraemic patients (Evidence: Moderate) 10 3. Incorporate IgG subclass analysis (IgG1, IgG3, IgG4) in diagnostic workup to differentiate between active and resolved infections, aiding in clinical management decisions (Evidence: Moderate) 1423 4. Prioritize the use of BmR1 recombinant antigen-based IgG4 ELISA for rapid diagnosis and monitoring of Brugia malayi infections due to its high sensitivity and specificity (Evidence: Moderate) 16 5. Consider combining IgG4 ELISA with PCR-ELISA for comprehensive diagnosis in low-endemicity areas where traditional microscopy may not be reliable (Evidence: Moderate) 18 6. Establish baseline serological profiles for individuals exposed to Brugian filariasis to facilitate pre-transmission assessment surveys and treatment monitoring (Evidence: Moderate) 1 7. Evaluate IgG isotype responses against Wolbachia hsp60 in individuals exposed to Brugia malayi to understand immune interactions with endosymbiotic bacteria (Evidence: Moderate) 13 8. Monitor antibody titers in MDA-compliant subjects to assess treatment efficacy and identify potential relapse risks, with a focus on IgG4 levels below 50 IU/mL indicating successful clearance (Evidence: Moderate) 10 9. Utilize loop-mediated isothermal amplification (LAMP) for rapid detection of circulating filarial antigens in asymptomatic individuals to aid early diagnosis (Evidence: Moderate) 3 10. Implement serological screening programs targeting IgG subclasses specifically in populations with chronic elephantiasis to guide targeted therapeutic interventions (Evidence: Moderate) 23
References
1 Mensah DA, Opoku VS, Boateng J, Opoku J, Osei-Mensah J, Gyasi C et al.. Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys. PLoS neglected tropical diseases 2025. link 2 Evans CC, Pilotte N, Moorhead AR. Current Status of the Diagnosis of Brugia spp. Infections. Pathogens (Basel, Switzerland) 2024. link 3 Poole CB, Tanner NA, Zhang Y, Evans TC, Carlow CK. Diagnosis of brugian filariasis by loop-mediated isothermal amplification. PLoS neglected tropical diseases 2012. link 4 Melnikow E, Xu S, Liu J, Li L, Oksov Y, Ghedin E et al.. Interaction of a Wolbachia WSP-like protein with a nuclear-encoded protein of Brugia malayi. International journal for parasitology 2011. link 5 Semnani RT, Venugopal PG, Mahapatra L, Skinner JA, Meylan F, Chien D et al.. Induction of TRAIL- and TNF-alpha-dependent apoptosis in human monocyte-derived dendritic cells by microfilariae of Brugia malayi. Journal of immunology (Baltimore, Md. : 1950) 2008. link 6 Gnanasekar M, Padmavathi B, Ramaswamy K. Cloning and characterization of a novel immunogenic protein 3 (NIP3) from Brugia malayi by immuno screening of a phage-display cDNA expression library. Parasitology research 2005. link 7 Yenbutr P, Scott AL. Molecular cloning of a serine proteinase inhibitor from Brugia malayi. Infection and immunity 1995. link 8 Jeffers GW, Klei TR, Enright FM. Activation of jird (Meriones unguiculatus) macrophages by the filarial parasite Brugia pahangi. Infection and immunity 1984. link 9 Jawaharlal JP, Madhumathi J, Prince RP, Kaliraj P. Repeat region of Brugia malayi sheath protein (Shp-1) carries Dominant B epitopes recognized in filarial endemic population. Acta parasitologica 2014. link 10 Jiraamonnimit C, Wongkamchai S, Boitano J, Nochot H, Loymek S, Chujun S et al.. A cohort study on anti-filarial IgG4 and its assessment in good and uncertain MDA-compliant subjects in brugian filariasis endemic areas in southern Thailand. Journal of helminthology 2009. link 11 Verma SK, Bansal I, Vedi S, Saxena JK, Katoch VM, Bhattacharya SM. Molecular cloning, purification and characterisation of myosin of human lymphatic filarial parasite Brugia malayi. Parasitology research 2008. link 12 Jiang D, Li BW, Fischer PU, Weil GJ. Localization of gender-regulated gene expression in the filarial nematode Brugia malayi. International journal for parasitology 2008. link 13 Suba N, Shiny C, Taylor MJ, Narayanan RB. Brugia malayi Wolbachia hsp60 IgG antibody and isotype reactivity in different clinical groups infected or exposed to human bancroftian lymphatic filariasis. Experimental parasitology 2007. link 14 Wongkamchai S, Rochjanawatsiriroj C, Monkong N, Nochot H, Loymek S, Jiraamornnimit C et al.. Diagnostic value of IgG isotype responses against Brugia malayi antifilarial antibodies in the clinical spectrum of brugian filariasis. Journal of helminthology 2006. link 15 Khan MA, Gaur RL, Dixit S, Saleemuddin M, Murthy PK. Responses of Mastomys coucha, that have been infected with Brugia malayi and treated with diethylcarbamazine or albendazole, to re-exposure to infection. Annals of tropical medicine and parasitology 2004. link 16 Noordin R, Shenoy RK, Rahman RA. Comparison of two IgG4 assay formats (ELISA and rapid dipstick test) for detection of brugian filariasis. The Southeast Asian journal of tropical medicine and public health 2003. link 17 Lawrence RA, Allen JE, Gray CA. Requirements for in vivo IFN-gamma induction by live microfilariae of the parasitic nematode, Brugia malayi. Parasitology 2000. link 18 Rahmah N, Ashikin AN, Anuar AK, Ariff RH, Abdullah B, Chan GT et al.. PCR-ELISA for the detection of Brugia malayi infection using finger-prick blood. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998. link91066-5) 19 Schmitz KA, Hale TJ, Rajan TV, Yates JA. Localization of paramyosin, myosin, and a heat shock protein 70 in larval and adult Brugia malayi. The Journal of parasitology 1996. link 20 Rajan TV, Shultz LD, Yates J, Greiner DL. B lymphocytes are not required for murine resistance to the human filarial parasite, Brugia malayi. The Journal of parasitology 1995. link 21 Lawrence RA, Allen JE, Gregory WF, Kopf M, Maizels RM. Infection of IL-4-deficient mice with the parasitic nematode Brugia malayi demonstrates that host resistance is not dependent on a T helper 2-dominated immune response. Journal of immunology (Baltimore, Md. : 1950) 1995. link 22 Chenthamarakshan V, Cheirmaraj K, Reddy MV, Harinath BC. Analysis and diagnostic use of Brugia malayi adult antigen in bancroftian filariasis. The Journal of tropical medicine and hygiene 1995. link 23 Rahmah N, Anuar AK, Karim R, Mehdi R, Sinniah B, Omar AW. Potential use of IgG2-ELISA in the diagnosis of chronic elephantiasis and IgG4-ELISA in the follow-up of microfilaraemic patients infected with Brugia malayi. Biochemical and biophysical research communications 1994. link 24 Chandrashekar R, Curtis KC, Ramzy RM, Liftis F, Li BW, Weil GJ. Molecular cloning of Brugia malayi antigens for diagnosis of lymphatic filariasis. Molecular and biochemical parasitology 1994. link00035-2) 25 Rajan TV, Nelson FK, Killeen N, Shultz LD, Yates JA, Bailis JM et al.. CD4+ T-lymphocytes are not required for murine resistance to the human filarial parasite, Brugia malayi. Experimental parasitology 1994. link 26 Crandall R, Crandall C, Nayar J, Doyle T. Resistance and disease in Brugia malayi infection of ferrets following prior infection, injection of attenuated infective larvae and injections of larval extracts. Parasite immunology 1994. link 27 Lawrence RA, Denham DA. Stage and isotype specific immune responses in a rat model of filariasis. Parasite immunology 1993. link 28 Fletcher C, Wu CC. Antibodies against somatic antigens and excreted/secreted products of Brugia pahangi in rats with patent and non-patent infections. Parasitology 1992. link 29 Chandrashekar R, Subrahmanyam D, Weil GJ. Effect of CGP 20376 on Brugia malayi and parasite antigenemia in jirds. The Journal of parasitology 1991. link 30 Farrar RG, Klei TR, McVay CS, Coleman SU. Qualitative characterization of antibody responses to single and multiple Brugia pahangi infections in jirds. The Journal of parasitology 1991. link 31 Lal RB. Monoclonal antibodies to secreted antigens of Brugia malayi define a cross-reactive non-phosphocholine determinant on helminth parasites. Immunology and cell biology 1991. link 32 Cheirmaraj K, Harinath BC. Humoral immune response to infective larval antigen in Brugia malayi infected Mastomys natalensis. Acta tropica 1991. link90018-f) 33 Weil GJ, Chandrashekar R, Liftis F, McVay CS, Bosshardt SC, Klei TR. Circulating parasite antigen in Brugia pahangi-infected jirds. The Journal of parasitology 1990. link 34 Chandrashekar R, Yates JA, Weil GJ. Use of parasite antigen detection to monitor macrofilaricidal therapy in Brugia malayi-infected jirds. The Journal of parasitology 1990. link 35 Kwan-Lim GE, Maizels RM. MHC and non-MHC-restricted recognition of filarial surface antigens in mice transplanted with adult Brugia malayi parasites. Journal of immunology (Baltimore, Md. : 1950) 1990. link 36 Kurniawan L, Basundari E, Fuhrman JA, Turner H, Purtoma H, Piessens WF. Differential recognition of microfilarial antigens by sera from immigrants into an area endemic for brugian filariasis. Parasite immunology 1990. link 37 Klei TR, McVay CS, Dennis VA, Coleman SU, Enright FM, Casey HW. Brugia pahangi: effects of duration of infection and parasite burden on lymphatic lesion severity, granulomatous hypersensitivity, and immune responses in jirds (Meriones unguiculatus). Experimental parasitology 1990. link90065-k) 38 McVay CS, Klei TR, Coleman SU, Bosshardt SC. A comparison of host responses of the Mongolian jird to infections of Brugia malayi and B. pahangi. The American journal of tropical medicine and hygiene 1990. link 39 Kwan-Lim GE, Gregory WF, Selkirk ME, Partono F, Maizels RM. Secreted antigens of filarial nematodes: a survey and characterization of in vitro excreted/secreted products of adult Brugia malayi. Parasite immunology 1989. link 40 Fuhrman JA, Piessens WF. A stage-specific calcium-binding protein from microfilariae of Brugia malayi (Filariidae). Molecular and biochemical parasitology 1989. link90211-9) 41 Weil GJ. Brugia malayi: detection of parasite antigen in sera from infected jirds. Experimental parasitology 1988. link90008-2) 42 Wenger JD, Forsyth KP, Kazura JW. Identification of phosphorylcholine epitope-containing antigens in Brugia malayi and relation of serum epitope levels to infection status of jirds with brugian filariasis. The American journal of tropical medicine and hygiene 1988. link 43 Snowden K, Hammerberg B. Dynamics of immune responses related to clinical status in Brugia pahangi-infected dogs. The American journal of tropical medicine and hygiene 1987. link 44 Fuhrman JA, Urioste SS, Hamill B, Spielman A, Piessens WF. Functional and antigenic maturation of Brugia malayi microfilariae. The American journal of tropical medicine and hygiene 1987. link 45 Fletcher C, Birch DW, Samad R, Denham DA. Brugia pahangi infections in cats: antibody responses which correlate with the change from the microfilaraemic to the amicrofilaraemic state. Parasite immunology 1986. link 46 Tomisato M, Nariuchi H, Ueno J, Nogami S, Tanaka H, Aoki Y et al.. Brugia pahangi: stage-specific antigens on microfilariae detected by serum from infected jirds or by monoclonal antibodies. Experimental parasitology 1986. link90130-x) 47 Tandon A, Zahner H, Sänger I, Müller HA, Reiner G. Time courses of antibody levels in Mastomys natalensis after infections with Litomosoides carinii, Dipetalonema viteae, Brugia malayi or B. pahangi, Determined by ELISA. Zeitschrift fur Parasitenkunde (Berlin, Germany) 1983. link 48 Crandall RB, Crandall CA, Neilson JT, Fletcher JT, Kozek WW, Redington B. Antibody responses to experimental Brugia malayi infections in patas and rhesus monkeys. Acta tropica 1983. link 49 Spencer HC, Collins WE, Stanfill PS, Huong AY, Barber AM, Contacos PG. Antibody response to heterologous and homologous antigens in Brugia malayi- and B. pahangi-infected Mongolian jirds as measured by the enzyme-linked immunosorbent assay (ELISA). The American journal of tropical medicine and hygiene 1981. link 50 Suswillo RR, Doenhoff MJ, Denham DA. Successful development of Brugia pahangi in T-cell deprived CBA mice. Acta tropica 1981. link 51 Singh M, Kane GJ, Burren C, Mackinlay LM. Immunofluorescent studies in filariasis: antibody levels in jirds (Meriones unguiculatus) infected with Brugia malayi. Journal of helminthology 1980. link 52 McGreevy PB, Ismail MM, Phillips TM, Denham DA. Studies with Brugia pahangi 10. An attempt to demonstrate the sharing of antigenic determinants between the worm and its hosts. Journal of helminthology 1975. link